ArticleOncology letters2019
Mutations in exon 8 of
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.Nature communications · 2021Trial
- Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review.Cancers · 2026Review
- First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation.BMC cancer · 2024Article
- Bioinformatic Identification of TP53 Gene Mutation Hotspots in Colorectal Cancer.International journal of molecular sciences · 2024Article
- Immune landscape in APC and TP53 related tumor microenvironment in colon adenocarcinoma: A bioinformatic analysis.European journal of microbiology & immunology · 2024Article
- Genetic Factors and MicroRNAs in the Development of Gallbladder Cancer: The Prospective Clinical Targets.Current drug targets · 2024Review
- Prognostic Role ofDiagnostics (Basel, Switzerland) · 2023Review
- Concordance of Abundance for MutationalCurrent oncology (Toronto, Ont.) · 2023Article
- Chronic Exposure to Nitric Oxide Induces P53 Mutations and Malignant-like Features in Human Breast Epithelial Cells.Biomolecules · 2023Article
- Daily Practice Assessment ofCancers · 2022Review
- [Research Advances of EGFR-TP53 Co-mutation in Advanced Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- The Role ofCancers · 2022Review
- Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a NovelFrontiers in oncology · 2022Article
- Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.BMC pulmonary medicine · 2021Article
- Prognostic Value of theCancer management and research · 2021Article
- Mutation Spectrum ofPathology oncology research : POR · 2021Article
- ConcomitantJournal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, in clinical settings, all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.